Figure 4.
(A∼E) Clinical timelines for the five representative ER-positive metastatic breast cancer patients harboring ESR1 mutations. The dynamic changes of ESR1 mutation levels were compared with serum tumor marker levels along with treatment.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.